Our client was developing a novel cellular therapy with promising Phase I safety data and some evidence of efficacy across a number of indications. To inform its clinical development plan, it engaged Prescient to determine which of the six indications it was considering had the most commercial potential and what the optimal launch order would be.

Shaping Decisions | Driving Value

We conducted a systematic data review to establish the competitor landscape in all six indications, highlighting each product’s strengths, weaknesses and market potential as well as expected launch timelines. The information was used to develop the key competitors’ target product profiles (TPPs). Next, we conducted interviews with KOLs in the key indications and across modalities to obtain feedback on our client’s clinical concept and how it compared with those of direct competitors. The KOLs also provided information on unmet needs, the size of the addressable market in each indication, clinical endpoints and patient profiles. The insights generated were used to identify a number of parameters (in a scorecard approach) to assess the commercial potential of our client’s product in each indication as well as the optimal sequencing of the indications.

The Prescient Advantage

Our client used the research to inform its clinical trial development and indication sequencing plan by merging information about the clinical landscape with commercial elements. Not only did we highlight the unmet needs where the client’s technology could resonate the most, but we also used our breadth of expertise to gain insights into other disruptive technologies and identify an opportunity for differentiation vis-à-vis the entire competitive set. We suggested development strategies for each indication, and the product is currently being tested in the first indication that our research indicated as “priority”. In addition, the client is using the insights we generated to conduct highly scientific discussions with KOLs on this emerging and exciting technology.